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Abstract
Background: Rhesus macaques infected with lymphocytic choriomeningitis virus (LCMV) provide
a model for human Lassa fever. Disease begins with flu-like symptoms and progresses rapidly with
fatal consequences. Previously, we profiled the blood transcriptome of LCMV-infected monkeys
(M. Djavani et al J. Virol. 2007) showing distinct pre-viremic and viremic stages that discriminated
virulent from benign infections. In the present study, changes in liver gene expression from
macaques infected with virulent LCMV-WE were compared to gene expression in uninfected
monkeys as well as to monkeys that were infected but not diseased.
Results: Based on a functional pathway analysis of differentially expressed genes, virulent LCMV-
WE had a broader effect on liver cell function than did infection with non-virulent LCMV-
Armstrong. During the first few days after infection, LCMV altered expression of genes associated
with energy production, including fatty acid and glucose metabolism. The transcriptome profile
resembled that of an organism in starvation: mRNA for acetyl-CoA carboxylase, a key enzyme of
fatty acid synthesis was reduced while genes for enzymes in gluconeogenesis were up-regulated.
Expression was also altered for genes associated with complement and coagulation cascades, and
with signaling pathways involving STAT1 and TGF-β.
Conclusion: Most of the 4500 differentially expressed transcripts represented a general response
to both virulent and mild infections. However, approximately 250 of these transcripts had
significantly different expression in virulent infections as compared to mild infections, with
approximately 30 of these being differentially regulated during the pre-viremic stage of infection.
The genes that are expressed early and differently in mild and virulent disease are potential
biomarkers for prognosis and triage of acute viral disease.
Background
Arenaviruses are rodent-borne viruses that can be trans-
mitted to primates, occasionally causing lethal hemor-
rhagic fever. Arenaviruses causing Lassa fever and South
American hemorrhagic fevers have been classified as Cat-
egory A bio-threats in the United States because of their
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virulence. Human beings infected with a hemorrhagic
fever virus initially exhibit flu-like symptoms, and disease
progresses so rapidly that diagnosis and appropriate treat-
ments are often too late. Laboratory studies using the are-
navirus lymphocytic choriomeningitis virus (strain
LCMV-WE) showed that rhesus macaques develop an
acute viral disease similar to Lassa fever in human beings
[1-8]. LCMV-associated hemorrhagic fever in macaques
provided a practical model for disease in a well-controlled
laboratory environment. Whereas LCMV-WE was highly
pathogenic for primates and guinea pigs, animals infected
with the Armstrong strain (LCMV-ARM) did not manifest
disease or viremia and were protected from lethal chal-
lenge with LCMV-WE [8].
Our previous publications on the pathology of LCMV-WE
infection described up-regulation of liver gene expression
related to organ development, regeneration and inflam-
matory responses [2,3,5]. Blood profiles of LCMV-
infected macaques revealed distinct pre-viremic and
viremic stages of infection, with over 90 virulence-specific
gene-expression changes detectable before the viremic
stage [3]. The viremic or symptomatic stage of the virulent
infection was characterized by high viral loads, high liver
enzymes, thromocytopenia, high plasma levels of IP-10,
IFN-γ, MCP-1, IL-6, TNFRI and TNFRII, as well as clinical
signs of appetite loss, withdrawal, and fever [2-6,8]. Dis-
eased liver tissue had disorganized parenchyma and
mononuclear infiltrates (infiltrates were also seen in
lung), whereas tissue from animals that were infected but
not diseased had no infiltrates and appeared healthy [4-
6]. Gene expression of PBMC was remarkable for its
down-regulation of several signaling pathways, e.g. via IL-
1β receptor, epithelial growth factor receptor, and retinoic
acid receptor [3] and this decrease was corroborated by
studies in a guinea pig model for Lassa fever [9,10]. A dra-
matic and early drop in cyclo-oxygenase-2 gene (PTGS2)
expression was observed in the primate model that could
directly account for the drop in prostacyclin and platelet
dysfunction described in Lassa fever [11-13].
Despite the complex clinical presentation of viral hemor-
rhagic fever, we chose to focus on liver gene expression
because that organ had the highest virus titers. Liver tissue
contains several cell types, and approximately 25% of the
changes in transcriptome do not result in proteomic
changes [14]; so with these caveats in mind, we examine
the most prominent transcriptome changes in relation to
published information about primate liver infections.
Down-regulated genes involved in fatty acid synthesis and
up-regulated genes involved in gluconeogenesis presented
a profile that has been associated with starvation and also
typifies LCMV infection of macaques. Although most of
the gene expression changes controlling intermediary
metabolism could be categorized as general homeostatic
responses to infection, some gene-expression changes,
such as in transcripts related to amino-acid catabolism
and protein phosphatase, were strongly associated with
an early virulent profile and were more likely to contrib-
ute to fatal disease. Approximately 30 genes were identi-
fied as potential signature biomarkers for the onset of
virulent LCMV-related liver disease. We discuss those gene
expression changes that are similar to other viral diseases
of liver and those changes that seem unique to an acute
arenavirus infection.
Materials and methods
Experimental samples
Twenty healthy adult rhesus macaques, five to nine years
of age, were used for a terminal study [3]. Liver tissue sam-
ples were obtained on the day of euthanasia, from unin-
fected controls and infected animals. Before euthanasia,
blood was taken for clinical chemistry and hematology;
tissues were processed for RNA extraction within 15 min-
utes after collection.
LCMV infection of rhesus macaques was described previ-
ously [3]. Briefly, animals were either uninfected or
infected intravenously (i.v.) with LCMV-ARM or LCMV-
WE using 103 plaque forming units (pfu) virus. LCMV-WE
alone, at 103 pfu i.v. is uniformly lethal. Four animals
infected with both LCMV-ARM and LCMV-WE (103 pfu
each), did not develop symptoms and were classified as
"infected-but-not-diseased". Infection in macaques was
monitored by plaque assay of infectious particles in
plasma, by infectious center assay of PBMC and liver tis-
sues, and by RT-PCR to detect viral RNA in tissues [3].
RNA preparation and GeneChip hybridization
Total RNA was prepared from LCMV-infected or unin-
fected liver tissues following TRIzol (GIBCO-BRL) extrac-
tion and purification using an RNeasy system according to
the manufacturer's instructions (QIAGEN, Valencia, CA).
A QIAGEN RNase-free DNase supplement kit was used to
ensure that the RNA had no DNA contamination. All RNA
samples were checked for both quality and quantity as
described previously [3]. RNA that passed this initial qual-
ity control screen was then labeled according to the stand-
ard target labeling protocols provided by Affymetrix and
hybridized to the GeneChip human genome U133 Plus
2.0 array (Affymetrix, Santa Clara, CA) as described by the
manufacturer http://www.affymetrix.com. The use of the
Affymetrix human genome microarrays for monitoring
transcriptome changes in rhesus macaque tissues has been
validated by other studies [15-17].
Microarray data analysis
Microarray data analyses were performed using the Array
Data Analysis and Management System (ADAMS), cur-
rently being developed at VBI http://pathport.vbi.vt.edu.Virology Journal 2009, 6:20 http://www.virologyj.com/content/6/1/20
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The system uses publicly available tools for analysis of the
data. Briefly, raw probe intensities were normalized and
summarized using a robust multichip average of G+C
content algorithm (gcRMA algorithm) [18]. Detection
calls (present, marginal, or absent) for each probe set were
obtained using the mas5calls function in the Affy R pack-
age [19]. For paired comparisons, only genes with at least
one present call among the compared samples were
included.
A total of 20 samples were used to generate the microarray
data http://www.ncbi.nlm.nih.gov/geo. Data from the 20
samples were grouped as follows to perform statistical
analyses: uninfected controls (three samples), samples
infected with the virulent strain LCMV-WE taken during
the pre-viremic stage (four samples), samples infected
with LCMV-WE during the viremic stage (five samples),
samples infected with LCMV-WE during the post-viremic
stage (two samples), and six samples that were infected
but not diseased (two monkeys infected with LCMV-ARM
and four infected with both LCMV-ARM and LCMV-WE)
(Table 1). Cluster analysis justified grouping LCMV-ARM
samples with LCMV-ARM+WE samples since heat maps of
gene expression from LCMV-ARM-infected animals were
most similar to those from animals doubly-infected with
LCMV-ARM and LCMV-WE (see Additional File 1). Mean
n-fold changes were calculated using a division of normal-
ized expression values between experimental sample and
uninfected control. False discovery rates [20] of the pair-
wise comparisons were calculated using p-values from the
Linear Models for Microarray Data (LIMMA) package
[designed for analysis of Affymetrix array data; http://bio
inf.wehi.edu.au/affylmGUI/]. Differentially-regulated
genes were selected using a 2-fold cut-off and a false dis-
covery rate (FDR) of < 0.05.
Table 1: Macaque liver tissues used for transcriptome analyses
Liver samples AST/ALTd Glucosee Triglyceridesf Virus titerg
Uninfected controls
Rh Ctrl7 38/65 74 65 <102
Rh Ctrl8 24/53 79 61 <102
Rh Ctrl9 47/71 87 77 <102
LCMV-WE1-Pre-viremic
Rh 1WE (day 1)a 44/61 53 27 <102
Rh 2WE (day 1) 63/54 58 30 <102
Rh 3WE (day 2) 59/37 60 18 <102
Rh 5WE (day 3) 27/71 62 37 <102
LCMV-WE2-Viremicb
Rh 6WE (day 4) 96/137 71 33 <102
Rh 7WE (day 4) 24/38 67 18 <102
Rh 8WE (day 6) 26/56 54 32 1.4 × 104
Rh 9WE (day 6) 125/82 70 31 5.0 × 103
Rh 10WE (day 7) 190/325 66 30 1.5 × 106
LCMV-WE3 Terminal
Rh 11WE (day 11) 642/587 30 235 5.5 × 105
Rh 12WE (day 12) 1504/681 40 1402 1.0 × 106
LCMV-not diseasedc
Rh 3ARM (day 3) 45/74 70 75 <102
Rh 5ARM (day 5) 18/40 78 62 <102
Rh 1ARM/WE-1 52/24 65 79 <102
Rh 1ARM/WE-5 Not done Not done ND <102
Rh 2ARM/WE-6 56/34 63 80 <102
Rh 2ARM/WE-2 Not done Not done ND <102
a (day 1) is the day of necropsy after infection. Each sample is from the liver of a different rhesus macaque.
b Pre-viremic means liver was harvested day 1, day 2 or day 3 after infection; Viremic means liver was harvested day 4 to day 7, and Terminal means 
liver was harvested day 11 or 12 during the terminal stage of disease. ND = Not done.
c Animals that were LCMV-infected but not diseased were either infected with LCMV-ARM and sacrificed day 3 or day 5 after infection, or they 
were infected with LCMV-ARM and LCMV-WE (103 pfu each virus) and sacrificed on day 30 after infection.
d AST/ALT means the ratio of plasma levels of aspartate aminotransferase to alanyl aminotransferase in international units per liter (IU/L). Normal 
ranges are AST/ALT = 18–82/22–87 IU/L. Values outside the reference range are bolded.
e Serum glucose levels are in mg/dL with a reference range of 55–80 mg/dL (Animal Diagnostics Laboratory, Baltimore, MD.)
f Serum triglyceride levels have a reference range of 50–82 mg/dL. Other parameters derived from blood analysis include red blood cells, 
hemoglobin levels and cholesterol levels which were all within normal ranges for all samples.
g Virus was titered on Vero cell monolayers as described [2], and given as plaque forming units per gram of liver tissue. Samples in the viremic group 
that had undetectable titers (<102 pfu/gm) were positive for virus nucleic acid by RT-PCR and virus co-cultivation as described previously [3].Virology Journal 2009, 6:20 http://www.virologyj.com/content/6/1/20
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Pairwise comparisons were performed to identify 3,125
differentially-regulated genes (n-fold of at least 2 and FDR
P < 0.05) between infected samples (n = 9) and uninfected
control samples (n = 3) or between infected samples (n =
9) and samples from animals that were infected but not
diseased (n = 6). Six separate pair-wise comparisons were
also performed to compare the three groups of infected
samples: pre-viremic (n = 4), viremic (n = 5) and post-
viremic (n = 2) to the two groups; controls (n = 3) or non-
diseased samples (n = 6). These six pairwise comparisons
resulted in identification of 4,482 differentially-regulated
genes (n-fold of at least 2 and FDR P < 0.05) amongst any
one pairwise comparison. KEGG software was used to
identify key functions and metabolic pathways differen-
tially-regulated between uninfected and LCMV-infected
liver samples. The raw gene expression data and the
related experimental information from this study can be
found at http://www.ncbi.nlm.nih.gov/geo, platform
number GSE12254.
Quantitative real-time reverse-transcriptase PCR
Genes for microarray analysis were validated by quantita-
tive real-time PCR as we described [3] to determine the
extent to which gene expression was up- or down-regu-
lated as a result of infection. Monkey and human-specific
primers were used to validate expression levels for selected
host genes. Although we ordinarily used primers derived
from GAPDH, Actin, or 18S RNA for baseline expression,
we found that the expression of these three genes varied in
infected versus uninfected liver, so we searched for genes
that were expressed in liver but at a steady level for all
infection time-points. We found that expression of the
protein kinase C substrate 80 K-H gene (PRKCSH, or
hepatocystin) had a less than 0.04-fold standard deviation
over all the samples used for this liver transcriptome anal-
ysis. Baseline expression of PRKCSH could be determined
with primers for the Macaca mulatta sequence (first, CGT-
TAGGCAGCCGTGC and second, GGCCGTGGAGGT-
CAAGAGGC).
Results
Identification of differentially-regulated genes in LCMV-
infected rhesus macaque liver
Liver RNA from LCMV-infected macaques was used for
transcriptome profiling with the goal of identifying gene
expression that differentiated infected from uninfected
liver and that differentiated virulently-infected (diseased)
from mildly-infected (non-diseased) liver. As described
previously [3], we characterized two major stages of infec-
tion, pre-viremic (day 1 to day 3) and viremic (day 4 to
day 7) and compared them to uninfected samples or sam-
ples from monkeys infected with LCMV that did not have
disease. Three types of results are presented here: 1) genes
with the greatest differential expression after pair-wise
comparisons of infected and uninfected liver samples, 2)
gene expression associated with major pathways in the
liver such as gluconeogenic, glycolytic, lipogenic and
coagulation pathways, and 3) genes with the greatest dif-
ferential expression after pair-wise comparison of virulent
and mildly-infected samples. In the latter category we
especially noted gene expression changes that occurred
before the viremic stage of disease, and could potentially
serve as biomarkers that discriminate between virulent
and benign infections.
The liver is highly vascularized and sensitive to changes in
blood composition. Since liver tissue contains a mixture
of cells including hematopoietic cells found in the circu-
lation, we examined the overlap of gene expression in
liver and in blood for the virulently-infected monkeys
(Figure 1; Additional Files 2, 3, 4, 5, 6, 7). Among the sub-
set of genes displaying comparably elevated expression in
blood and liver were interferon-induced transmembrane
protein 1 (IFITM1), tumor necrosis factor (ligand) super-
family, member 10 (TNFSF10, or TRAIL), ubiquitin-con-
jugating enzyme E2L6 (UBE2L6), BCL2-related protein
A1 (BCL2A1), profilin 1 (PFN1), some coagulation path-
way genes, and some JAK-STAT/toll-like receptor signaling
pathway genes.
Additional File 8 lists differentially-regulated genes in
macaque liver (n = 4482), which include 1234 signifi-
cantly (p < 0.05) up-regulated genes and 123 down-regu-
lated genes (the remainder were up-regulated at some
time points and down-regulated at others). Differential
gene expression is presented in two ways: 1) LCMV-WE-
infected (diseased) liver compared to uninfected liver,
and 2) LCMV-WE-infected (diseased) liver compared to
LCMV-infected non-diseased liver. Differentially-
expressed genes were defined as those that had at least a 2-
fold alteration in LCMV-infected livers compared to the
uninfected controls.
Genes with the highest differential expression between
LCMV-infected and uninfected livers (53 are listed in Fig-
ure 2) encode several heat shock proteins, ribosomal pro-
teins, energy-generating enzymes, and proteins known to
be involved in anti-microbial defense [e. g. Shwachman-
Bodian-Diamond syndrome (SBDS), complement (C1S),
and interferon-inducible genes (IFITM1, IFITM2)]. Prom-
inent genes associated with energy-generation include
HPD and GSL2 encoding enzymes that break down
amino acids. Also notable are two gene products with
anti-inflammatory functions: 1) HSP60 (encoded by
HSPD1) that down-regulates T-bet, NF-kappaB, and NFAT
and up-regulates GATA-3, leading to decreased secretion
of TNF-alpha [21], and 2) LTB4DH that encodes a dehy-
drogenase which inactivates several eicosanoids such as
leukotriene B4 [22].Virology Journal 2009, 6:20 http://www.virologyj.com/content/6/1/20
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Metabolic pathway gene expression in LCMV-infected 
rhesus macaques
To understand the metabolic responses to LCMV infec-
tion, changes in gene expression in macaque livers were
examined in relation to their associated metabolic path-
ways using the KEGG pathways analysis. Additional File 9
shows 32 of the most significantly affected pathways in
LCMV-infected macaque liver with respect to uninfected
liver for both pre-viremic and viremic stages of infection.
Four of these pathways are described here and shown in
(Tables 3,4,5 and 6).
The largest number of genes with altered expression con-
tribute to lipid and glucose metabolism, and hence to the
generation of energy for the organism. Key regulators of
cholesterol synthesis, the mRNA for 3-hydroxy-3-methyl-
glutaryl-CoA synthase 1 and 2 (HMGCS1, HMGCS2),
were up-regulated during LCMV infection. Nevertheless,
the liver-specific transporter gene APOAV was down-regu-
lated (Additional File 8) suggesting that transport of trig-
lycerides and cholesterol (via HDL/LDL) would be
decreased in LCMV-infected liver. This is corroborated by
lowered serum triglycerides during the pre-viremic and
viremic stages (averaging 28 mg/dL when the norm is 50–
82 mg/dL; Table 1). However blood chemistry showed
that cholesterol levels were not affected by LCMV infec-
tion, so several transcriptional changes were not obvi-
ously related to effects on downstream metabolic
products. A possibility is that increased energy-generating
activity was defeated by poor transport, or that post-tran-
scriptional regulation over-shadowed the rise in transcript
levels.
Effect of LCMV infection on glucose metabolism
Monkeys undergoing virulent infection had normal blood
glucose levels (except at the terminal stage; Table 1) up-
regulated numerous genes involved in carbohydrate
metabolism (Additional File 9, tables 3, 4, 5 and 6). Dur-
ing the pre-viremic stage of infection several genes were
up-regulated for enzymes involved in gluconeogenesis,
i.e. the breakdown of fatty acids, amino acids and pyru-
vate to make glucose (Figure 2, Tables  3, 4, 5, and 6). For
example, glucose-6-phosphatase (G6Pase) was up-regu-
lated in both pre-viremic and viremic stages, and fructose
1,6-bis phosphatase (FBP1) was four-fold up-regulated
only at the pre-viremic stage (Table 3). The increased glu-
coneogenesis during LCMV infection resembled that seen
during starvation [23] or cachexia [24], however the infec-
tion also up-regulated mRNA encoding glycolytic
enzymes (PGK1, GCK, GAPDH and ALDOB; Table 3) that
are usually down-regulated during a fast [25]. Simultane-
ous up-regulation of glycolytic and gluconeogenic
enzymes in infected animals could mean that sugar
metabolism is in a futile cycle and that the majority of
energy production during LCMV infection comes from
beta-oxidation of fatty acids (Tables 3, 4 and 5, Figure 3).
LCMV-infected liver up-regulated expression of glycogen
synthase 2 (GYS2) in both pre-viremic and viremic stages
of infection (Table 3) suggesting the possibility that glu-
cose storage was enhanced. Glycogen in the LCMV-
infected liver could also be derived from hydrolysis of trig-
lycerides in fat cells since several lipases and beta-oxida-
tion enzymes were up-regulated (Table 7) and
triglycerides in blood were unusually low (Table 1).
Venn diagram of gene expression in virulently-infected liver compared to virulently-infected blood Figure 1
Venn diagram of gene expression in virulently-infected liver compared to virulently-infected blood. Genes iden-
tified as being differentially-regulated in both blood and liver can be found in Additional Files 2, 3, 4, 5, 6, 7.
Pre-viremic Viremic
Blood Liver Blood Liver
2751 2033 500 3136 1722 963Virology Journal 2009, 6:20 http://www.virologyj.com/content/6/1/20
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The most differentially regulated genes in liver after infection of macaques with LCMV-WE Figure 2
The most differentially regulated genes in liver after infection of macaques with LCMV-WE. WE1 refers to pre-
viremic samples (day 1–3) and WE2 refers to viremic samples (day 4–7). Both WE1 and WE2 are compared with uninfected 
samples (WE1 vs uninf) using the sample numbers shown in Table 1. Nfold refers to fold up- or down- regulation of each gene 
expressed in a virulently-infected liver in relation to expression in an uninfected liver. The p values for these genes are all less 
than 0.05. This is a subset of Additional File 8.
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GenBank    Gene Description
Acc. # symbol
NM_001134 AFP Alpha-fetoprotein
D16931 ALB Albumin
NM_005589 ALDH6A1 Aldehyde dehydrogenase 6 family, member A1
AF202889 APOA5 Apolipoprotein A-V
AW188940 B2M Beta-2-microglobulin
BC007010 C1S Complement component 1, s subcomponent
AF367476 CCNL1 Cyclin L1
W80357 CPS1 Carbamoyl-phosphate synthetase 1, mitochondrial
NM_000099 CST3 Cystatin C (amyloid angiopathy and cerebral hemorrhage)
AA889653 DES Desmin
AW083133 EIF3S12 Eukaryotic translation initiation factor 3, subunit 12
NM_000120 EPHX1 Epoxide hydrolase 1, microsomal (xenobiotic)
BG545288 FGB Fibrinogen beta chain
AK022172 FMO5 Flavin containing monooxygenase 5
AI743037 FMR1 Fragile X mental retardation 1
AF110329 GLS2 Glutaminase 2 (liver, mitochondrial)
AB046780 GPAM Glycerol-3-phosphate acyltransferase, mitochondrial
U56250 GSTO1 Glutathione S-transferase omega 1
NM_015987 HEBP1 Heme binding protein 1
N32864 HINT1 Histidine triad nucleotide binding protein 1
NM_002150 HPD 4-hydroxyphenylpyruvate dioxygenase
BG612458 HSP90AB1 Heat shock protein 90kDa alpha class B member 1
AB034951 HSPA8 Heat shock 70kDa protein 8
BE256479 HSPD1 Heat shock 60kDa protein 1 (chaperonin)
NM_006417 IFI44 Interferon-induced protein 44
NM_001548 IFIT1 Interferon-induced protein with tetratricopeptide repeats 1
NM_000597 IGFBP2 Insulin-like growth factor binding protein 2, 36kDa
BE566894 LTB4DH Leukotriene B4 12-hydroxydehydrogenase
NM_002356 MARCKS Myristoylated alanine-rich protein kinase C substrate
BE880828 MCFD2 Multiple coagulation factor deficiency 2
NM_002415 MIF Macrophage migration inhibitory factor
NM_014078 MRPL13 Mitochondrial ribosomal protein L13
BF215996 MYO1B Myosin IB
AW172570 NMNAT3 Nicotinamide nucleotide adenylyltransferase 3
NM_018441 PECR Peroxisomal trans-2-enoyl-CoA reductase
N26005 PPP1R3C Protein phosphatase 1, regulatory (inhibitor) subunit 3C
NM_002787 PSMA2 Proteasome (prosome, macropain) subunit, alpha type, 2
BC003005 PTGES3 prostaglandin E synthase 3 (cytosolic)
NM_007104 RPL10A Ribosomal protein L10a 
NM_000991 RPL28 Ribosomal protein L28 
NM_001008 RPS4Y1 Ribosomal protein S4, Y-linked 1
NM_001012 RPS8 Ribosomal protein S8
BC010183 SBDS Shwachman-Bodian-Diamond syndrome
AF328864 SELS Selenoprotein S
NM_016275 SELT Selenoprotein T
BC022309 SERPINC1 Serpin peptidase inhibitor, clade C (antithrombin), member 1
AI734001 SEZ6L2 Seizure related 6 homolog (mouse)-like 2
NM_007108 TCEB2 Transcription elongation factor B (SIII), polypeptide 2 (elongin B))
BG104571 TM9SF3 Transmembrane 9 superfamily member 3
BF508371 TNFRSF1A Tumor necrosis factor receptor superfamily, member 1A
AI885873 TNPO2 Transportin 2 (importin 3, karyopherin beta 2b)
NM_016146 TRAPPC4 Trafficking protein particle complex 4
BF591611 ZADH2 Zinc binding alcohol dehydrogenase, domain containing 2Virology Journal 2009, 6:20 http://www.virologyj.com/content/6/1/20
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Effect of virulent infection on lipogenic pathway (fatty 
acid metabolism)
Mobilization of fat (lipolysis) is favored under conditions
of increased energy need, such as exercise, fasting, hypo-
thermia [23], or cachexia associated with cancer and AIDS
[24]. When triglycerides in adipose tissue are broken
down by lipase, then the fatty acids and glycerol are
released to the bloodstream. Genes involved in fatty acid
transport, albumin (ALB), myosin (MYO1B), and the
thrombospondin receptor (CD36), were up-regulated
during infection (Figure 2). In the mitochondria, fatty
acids undergo β-oxidation into two-carbon acetyl groups
attached to CoA [23]. During LCMV infection, genes for
fatty acid metabolic enzymes were strongly up-regulated:
thiolase (ACAT2), hydroxyacyl-CoA dehydrogenase
(HADHA), enoyl-CoA hydratase (ECHS1), and stearol-
CoA desaturase (SCD) (Tables 4 and 5). The only down-
regulated gene in the fatty acid metabolic group was
acetyl-CoA carboxylase (ACACB), a major regulator of
fatty acid synthesis [23]. This would predict that free fatty
acids arose more frequently by β-oxidation than by fatty
acid synthesis via ACACB (Figure 3; Table 5). In support
of that prediction, several cytochrome P450 isoforms
(CYP2A, -3A, -2B) were up-regulated that are known to
break down steroids and fats during the course of LCMV-
infection (Table 4) [26,27]. The down-regulation of
ACACB and the up-regulation of CYP26A1 have been val-
idated by quantitative PCR (Table 2).
Free fatty acids (FFA) stimulate key gluconeogenic
enzymes [28,29]. For example the enzyme encoded by
PCK is up-regulated by FFA and peroxisome proliferator-
activated receptor (encoded by PPAR) in hepatoma cells
[30]. However both PPAR and PCK are more up-regulated
in the mild (non-diseased) infections than in the virulent
infections (Additional File 8), contributing to the picture
that these changes in intermediary metabolism are a pro-
tective host response that is stronger in the non-diseased
cases.
The aldehyde dehydrogenases clear the blood of toxic
aldehydes by generating acetate, which can be converted
to acetyl CoA. Several aldehyde dehydrogenases are up-
regulated during infection, especially ALDH6A1, a liver
mitochondrial enzyme that catalyzes the breakdown of
malonate to propionyl – and acetyl-CoA, (up-regulated
37- and 22-fold in pre-viremic and viremic stages, Addi-
tional File 8). Levels of acetyl-CoA are central to the bal-
ance between carbohydrate and fat metabolism, so in the
LCMV-infected liver, it appears that the product of
ALDH6A1 could drive acetyl CoA into the cholesterol or
citric acid cycles to generate energy but not into fatty acid
synthesis due to down-regulated ACACB acting as a bot-
tleneck (Figure 3).
Ketone-body formation (ketogenesis) occurs during high
rates of fatty acid oxidation through generation of large
Table 2: Validation of microarray results by real-time PCRa
Gene Symbol WE vs uninfected WE vs no disease
(GenBank ID) Pre-viremic Viremic Stage Pre-viremic Viremic stage
ACACB (AI057637) -3.58/-5 -4.38/-5 -2.16/-2 -2.64/-2
ACVR1 (NM_001105) 10.85/15 7.62/12 7.46/11 5.24/10
ARG2 (U75667) 1.02/2 1.04/1 -12.13/-9 -11.88/-5
C1S (BC007010) 53.45/25 50.21/22 6.73/4.2 6.32/3.7
CYP26A1(NM_000783) 9.85/13 2.11/1.2 10.56/14 2.27/2.9
FGB (BG545288) 49.87/32 45.57/29 3.36/2.4 3.07/2.0
FST (NM_013409) -1.67/1.8 1.09/1.3 -16.8/-19 -9.25/-16
GOT1 (BC000498) 3.92/3.0 2.0/1.6 -6.54/-13 -12.82/-18
HBA1/HBA2 (V00489) 2.79/2 1.2/3.1 -12.91/-11 -30.06/-25
HSPB1 (NM_001540) 28.64/22 36.76/43 9.38/7.2 12.04/9.7
IFI44 (NM_006417) 19.43/14 198.1/166 3.71/4.0 37.79/21
INHBA (M13436) 1.71/1.9 -1.13/1.3 11.16/15 5.78/8.7
PPARGC1A (NM_013261) -1.22/1.0 3.01/1.9 -21.41/-9 -5.82/-3
PPP1R3C (N26005) 25.28/32 9.99/12 156.5/87 61.82/45
SDS (NM_006843) -1.97/1.7 -2.07/1.2 -32.22/-28 -33.82/-29
TGFBR1 (AA604375) 4.29/4.8 3.1/2.5 1.33/1.6 -1.04/1.5
PRKCSH (AI815793)< 2 / - b <2/- <2/- <2/-
a The numbers represent N-folds from Affychip data (most in Figure 4, all in Additional file 8) and N-fold by real-time PCR (Naffy/NPCR). N-folds by 
real-time PCR make use of liver RNA from uninfected, pre-viremic LCMV-WE-infected, viremic LCMV-WE-infected, and infected-but-not-diseased 
monkeys.
b PRKCSH is the gene symbol for protein kinase C substrate 80 K-H to which the PCR data are normalized. It is expressed in liver and has a less 
than 0.04 standard deviation over all samples used for this liver transcriptome analysis. (-) means it is the reference value.Virology Journal 2009, 6:20 http://www.virologyj.com/content/6/1/20
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amounts of acetyl-CoA in liver [23]. Ketone bodies, con-
sisting of acetoacetate, acetone and β-hydroxybutyrate,
serve as an alternative source of energy at low glucose lev-
els. Ketogenesis was likely higher in LCMV-WE infected
rhesus macaques than in the mildly-infected macaques
since fatty acid synthesis via acetyl-coenzyme A carboxy-
lase beta (ACACB) was more down-regulated in the viru-
lent infection (Figure 2; Table 5). Genes involved with
mitochondrial fatty acid oxidation, cholesterol synthesis
and ketogenesis (Table 3; Additional File 8), for example,
the hydroxy-3-methylglutaryl-CoA synthases (HMGCS1
and 2) were induced by LCMV infection. They condense
acetyl-CoA and acetoacetyl-CoA to form HMG-CoA, an
intermediate in the pathway for synthesis of ketone bod-
ies, a likely source of energy during LCMV-WE infection
(Table 5).
The expression of several lipase genes is strongly up-regu-
lated during LCMV-WE infection, suggesting a relation-
ship between up-regulation of beta-oxidation enzymes
and lipolysis in the infected livers (Table 6). In general, we
found that genes involved in degradation of lipids and
fatty acids were up-regulated while a key gene involved in
fatty acid synthesis was down-regulated.
Effect of LCMV infection on gene expression related to 
coagulation and complement cascade pathways
The complement and coagulation cascades interact and
modulate each other; both are affected during LCMV
infection. Although we do not present coagulation data
here, platelet defects and a mild thrombocytopenia were
documented during severe Lassa fever [11,12], and
macaques with virulent LCMV disease showed a marked
thrombocytopenia [4]. The transcriptome data (Table 7)
show over-expression of complement component 1
(C1S), an anti-thrombin peptide (SERPINC1), and fibrin-
ogen beta chain (FGB) during virulent infection. Over-
expression of C1S and FGB have been validated by quan-
Table 3: Expression of genes involved with TCA cycle and glucose metabolism in LCMV-WE infected macaque liver
Pre-viremic Viremic
GenBank Accession no. Symbol Gene description Fold changea pb Fold changea pb
Citric acid cycle
NM_001096 ACLY ATP citrate lyase 2.14 0.0809 3.58 0.0040
AI363836 FH Fumarate hydratase 5.54 0.0045 3.05 0.0356
AI826060 IDH3A Isocitrate dehydrogenase 3 (NAD+) alpha 1.51 0.4150 2.29 0.0440
AF023266 IDH3B Isocitrate dehydrogenase 3 (NAD+) beta 2.41 0.0219 2.19 0.0290
NM_004135 IDH3G Isocitrate dehydrogenase 3 (NAD+) gamma 2.14 0.0262 2.29 0.0122
NM_005917 MDH1 Malate dehydrogenase 1, NAD (soluble) 9.51 0.0056 9.25 0.0039
BC001917 MDH2 Malate dehydrogenase 2, NAD (mitochondrial) 2.77 0.0739 3.48 0.0221
NM_004168 SDHA Succinate dehydrogenase complex, A, flavoprotein 4.17 0.0108 4.03 0.0087
NM_003000 SDHB Succinate dehydrogenase complex, B, iron sulfur 5.98 0.0120 6.68 0.0056
AF080579 SDHC Succinate dehydrogenase complex, C, membrane 
protein
14.12 0.0003 11.63 0.0003
AL050226 SUCLG2 Succinate-CoA ligase, GDP-forming, beta 4.23 0.0108 2.83 0.0442
Glycolysis
NM_000034 ALDOA Aldolase A, fructose-bisphosphate 2.03 0.0136 3.05 0.0004
AK026411 ALDOB Aldolase B, fructose-bisphosphate 14.83 0.0002 6.02 0.0027
AK026525 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 6.59 0.0034 4.89 0.0066
M69051 GCK Glucokinase (hexokinase 4) 3.92 0.0010 1.01 0.9980
S81916 PGK1 Phosphoglycerate kinase 1 23.59 0.0009 23.43 0.0005
NM_002633 PGM1 Phosphoglucomutase 1 6.28 0.0038 5.03 0.0058
Glycogen metabolism
S70004 GYS2 Glycogen synthase 2, liver 9.65 0.0004 5.54 0.0020
NM_002863 PYGL Phosphorylase glycogen, liver 4.96 0.0120 3.14 0.0485
NM_002633 PGM1 Phosphoglucomutase 1 6.28 0.0038 5.03 0.0058
Gluconeogenesis
D26054 FBP1 Fructose-1,6-bisphosphatase 1 4.08 0.0061 1.59 0.1559
BC020700 G6PC Glucose-6-phosphatase, catalytic 12.13 0.0034 5.17 0.0265
Others
NM_000284 PDHA1 Pyruvate dehydrogenase (lipoamide) alpha 1 3.48 0.0769 4.53 0.0249
a Mean fold changes were calculated using a division of raw expression values between experimental sample and uninfected control.
b All samples were analyzed separately. Changes in gene expression with a cutoff of 2.0-fold increased or decreased expression was used and, the p-
value was calculated by Student's t-test. Data are displayed only where the, p ≤ 0.05. This p-value was used as a measure of the magnitude of the 
difference between groups and to determine significance of the modulation. The modulated genes in the pathway are listed in alphabetic order.Virology Journal 2009, 6:20 http://www.virologyj.com/content/6/1/20
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titative PCR (Table 2). These 3 genes alone would predict
problems with coagulation: high C1S should drive the
classical pathway of the complement cascade towards
more phagocyte recruitment and cell lysis, high serpin
should inhibit the intrinsic pathway of coagulation, and
high fibrinogen should overwhelm the fibrinolysis that
occurs during clot formation [31]. Additionally, the mul-
tiple coagulation factor deficiency 2 (MCFD2) gene is up-
regulated 11-fold in pre-viremic and 15-fold during the
viremic phase and is important in the secretion of coagu-
lation factors V and VIII [32]. In addition to these highly
over-expressed genes, there is modest up-regulation of
coagulation factors II, V, and X which should promote
coagulation and has been associated with consumptive
coagulopathy and disseminated intravascular coagulation
(DIC); although DIC has not been associated with Lassa
[13] as it has with other hemorrhagic virus infections like
Ebola fever [33]. We also observed down-modulation of a
Table 4: Expression of genes involved with fatty acid oxidation in LCMV-WE infected macaque liver
Pre-viremic Viremic
GenBank Accession no. Symbol Gene description Fold changea pb Fold changea pb
Mitochondrial {beta}-oxidation
BE897866 ACADSB Acyl-CoA dehydrogenase, short/branched chain 1.77 0.6240 -2.93 0.0190
NM_004453 ETFDH Electron-transferring flavoprotein dehydrogenase 3.10 0.0019 1.49 0.1412
NM_004092 ECHS1 Enoyl CoA hydratase, short chain, 1, mitochondrial 7.06 0.0110 4.79 0.0260
U04627 HADHA Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (trifunctional 
protein), alpha
3.43 0.0180 3.75 0.0086
Microsomal oxidation
AF182275 CYP2A6 Cytochrome P450, family 2, subfamily A, 
polypeptide 6
17.88 0.0008 7.21 0.0009
X06399 CYP2B6 Cytochrome P450, family 2, subfamily B, 
polypeptide 6
3.16 0.0079 -1.02 0.9980
NM_030878 CYP2C8 Cytochrome P450, family 2, subfamily C, 
polypeptide 8
3.51 0.0020 2.35 0.0147
NM_000106 CYP2D6 Cytochrome P450, family 2, subfamily D, 
polypeptide 6
7.78 0.0065 2.66 0.1530
AF182276 CYP2E1 Cytochrome P450, family 2, subfamily E, 
polypeptide 1
4.06 0.0150 2.87 0.0459
NM_000777 CYP3A5 Cytochrome P450, family 3, subfamily A, 
polypeptide 5
7.57 0.0005 6.36 0.0005
AF315325 CYP3A7 Cytochrome P450, family 3, subfamily A, 
polypeptide 7
11.39 0.0006 5.28 0.0050
Ketogenesis
BC000408 ACAT2 Acetyl-CoA acetyltransferase 2 
(acetoacetyl CoA thiolase)
6.10 0.0065 4.78 0.0107
BG035985 HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 
(soluble)
3.10 0.0198 4.69 0.0467
NM_005518 HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 
(mitochondrial)
5.16 0.0135 2.91 0.0748
BF224073 TCP1 T-complex 1 3.43 0.0332 2.50 0.0977
Peroxisomal oxidation
NM_003500 ACOX2 Acyl-CoA oxidase 2, branched chain 6.63 0.0019 3.12 0.0267
NM_004092 ECHS1 Enoyl CoA hydratase, short chain, 1, mitochondrial 7.06 0.0110 4.79 0.0260
U04627 HADHA Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (trifunctional 
protein), alpha
3.43 0.0180 3.75 0.0086
NM_005525 HSD11B1 Hydroxysteroid (11-beta) dehydrogenase 1 2.80 0.0325 2.20 0.0874
AL031228 HSD17B8 Hydroxysteroid (17-beta) dehydrogenase 8 2.80 0.0258 2.20 0.0620
Other peroxisomal proteins
AU147084 CAT Catalase 8.63 0.0028 5.78 0.0069
Others
NM_000072 CD36 CD36 molecule (thrombospondin receptor) 48.18 0.0001 16.11 0.0008
a Mean fold changes were calculated using a division of raw expression values between experimental sample and uninfected control.
b All samples were analyzed separately. Changes in gene expression with a cutoff of 2.0-fold increased or decreased expression was used and, the p-
value was calculated by Student's t-test. Data are displayed only where the, p ≤ 0.05. This p-value was used as a measure of the magnitude of the 
difference between groups and to determine significance of the modulation. The modulated genes in the pathway are listed in alphabetic order.Virology Journal 2009, 6:20 http://www.virologyj.com/content/6/1/20
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Table 5: Expression of genes involved with fatty acid, cholesterol and amino acid metabolism in LCMV-WE infected macaque liver.
Pre-viremic Viremic
GenBank Accession no. Symbol Gene description Fold changea pb Fold changea pb
Fatty acid metabolism
AI057637 ACACB Acetyl-Coenzyme A carboxylase beta -3.58 0.0103 -4.38 0.0027
NM_001096 ACLY ATP citrate lyase 2.14 0.0809 3.58 0.0040
AB032261 SCD Stearoyl-CoA desaturase (delta-9-desaturase) 2.06 0.0448 4.69 0.0420
Cholesterol metabolism
BC000408 ACAT2 Acetyl-CoA acetyltransferase 2 
(acetoacetyl CoA thiolase)
6.10 0.0065 4.78 0.0107
U40053 CYP51A1 Cytochrome P450, family 51, subfamily A, 
polypeptide 1
3.68 0.0622 12.04 0.0010
NM_014762 DHCR24 24-dehydrocholesterol reductase 5.28 0.0006 3.66 0.0021
BC003573 FDFT1 Farnesyl-diphosphate farnesyltransferase 1 5.70 0.0195 6.02 0.0011
NM_002004 FDPS Farnesyl diphosphate synthase 3.63 0.0218 5.03 0.0040
BG035985 HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 
(soluble)
3.01 0.0198 4.69 0.0467
NM_005336 HDLBP High density lipoprotein binding protein (vigilin) 4.96 0.0007 3.14 0.0042
AF478446 NR1H4 Nuclear receptor subfamily 1, group H, member 4 11.31 0.0003 10.48 0.0002
BF530535 SPCS2 Signal peptidase complex subunit 2 10.34 0.0009 8.28 0.0011
Amino acid metabolism
NM_000687 AHCY S-adenosylhomocysteine hydrolase 7.46 0.0005 4.03 0.0048
AF110329 GLS2 Glutaminase 2 30.06 0.0039 11.31 0.0201
NM_002080 GOT2 Glutamic-oxaloacetic transaminase 2, 
mitochondrial (aspartate aminotransferase 2)
4.53 0.0036 3.12 0.0140
NM_000531 OTC Ornithine carbamoyltransferase 4.47 0.0182 2.58 0.1090
a Mean fold changes were calculated using a division of raw expression values between experimental sample and uninfected control.
b All samples were analyzed separately. Changes in gene expression with a cutoff of 2.0-fold increased or decreased expression was used and, the p-
value was calculated by Student's t-test. Data are displayed only where the, p ≤ 0.05. This p-value was used as a measure of the magnitude of the 
difference between groups and to determine significance of the modulation. The modulated genes in the pathway are listed in alphabetic order.
Table 6: Expression of various lipase genes and genes involved with lipase activity in LCMV-WE infected macaque liver.
Pre-viremic Viremic
GenBank Accession no Symbol Gene description Fold changea pb Fold changea pb
NM_000483 APOC2 Apolipoprotein C-II 5.50 0.0003 3.53 0.0019
AK023348 GRN Granulin 1.84 0.0448 3.20 0.0007
NM_006854 KDELR2 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum 
protein retention receptor 2
7.46 0.0056 7.36 0.0038
NM_000235 LIPA Lipase A, lysosomal acid, cholesterol esterase 2.17 0.1350 4.08 0.0059
NM_006033 LIPG Lipase, endothelial 2.20 0.4480 2.55 0.2950
AF077198 LYPLA1 Lysophospholipase I 7.16 0.0006 3.81 0.0008
BC006230 MGLL Monoglyceride lipase 3.27 0.0090 2.73 0.0162
D83485 PDIA3 Protein disulfide isomerase family A, member 3 6.36 0.0028 7.46 0.0010
AL542253 PLA1A Phospholipase A1 member A 1.37 0.0035 3.01 0.0124
NM_000300 PLA2G2A Phospholipase A2, group IIA (platelets) 2.19 0.7700 26.17 0.0218
AF145020 PLAA Phospholipase A2-activating protein 3.51 0.0026 2.69 0.0077
NM_002937 RNASE4 Ribonuclease, RNase A family, 4 45.25 0.00008 25.81 0.0001
a Mean fold changes were calculated using a division of raw expression values between experimental sample and uninfected control.
b All samples were analyzed separately. Changes in gene expression with a cutoff of 2.0-fold increased or decreased expression was used and, the p-
value was calculated by Student's t-test. Data are displayed only where the, p ≤ 0.05. This p-value was used as a measure of the magnitude of the 
difference between groups and to determine significance of the modulation. The modulated genes in the pathway are listed in alphabetic order.Virology Journal 2009, 6:20 http://www.virologyj.com/content/6/1/20
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gene encoding kallikrein (KLKB1) that dilates blood ves-
sels and should prevent vessel leakage.
Gene expression profiling that discriminates between 
virulent and non-virulent virus infection in LCMV-infected 
liver
Genes that discriminate between virulent and non-viru-
lent infection, especially if they do so during the pre-
viremic stage, have the greatest potential as prognostic
biomarkers for severe arenaviral disease. Virulent and
non-virulent liver transcriptomes were compared by pool-
ing results from nine animals (LCMV-WE-infected) to
compare with six samples from animals that were LCMV-
infected but not diseased (two animals infected with
LCMV-ARM and four infected with both LCMV-WE and
LCMV-ARM that did not develop disease). In our study,
the transcriptome of non-diseased animals closely resem-
bled the transcriptome of animals infected with non-viru-
lent LCMV-ARM (see clustering in Additional File 1). Liver
gene expression profiles showed significant differences
between virulent and non-virulent infections (Figure 4).
We determined that approximately 244 genes signifi-
cantly discriminated non-virulent and virulent LCMV
infections, and of these, approximately 30 did so during
the pre-viremic stage of infection (Figure 4 and Additional
File 8). Notable are large drops in expression of hemo-
globin alpha and beta genes, despite up-regulation of
transferrin (TF) the product of which promotes iron
Subcellular localization and metabolic pathways of significantly-modulated genes in the fatty acid synthesis pathway during the  pre-viremic stage of LCMV-WE infection in macaque liver tissues Figure 3
Subcellular localization and metabolic pathways of significantly-modulated genes in the fatty acid synthesis 
pathway during the pre-viremic stage of LCMV-WE infection in macaque liver tissues. Red or green color corre-
sponds to up- or down-regulation of gene expression, respectively. ATP citrate lyase is encoded by ACLY (Tables 3 and 5), 
Acetyl-CoA carboxylase is encoded by ACACB (Table 4), thiolase is encoded by ACAT2 (Tables 3 and 4), 3-hydroxyacyl-CoA 
dehydrogenase is encoded by HADHA (Table 4), enoyl-CoA hydratase is encoded by ECHS1 (Table 4) and acyl-CoA desatu-
rase is encoded by SCD (Table 5).
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absorption and hemoglobin production [34]. Down-reg-
ulation of hemoglobin is concomitant with up-regulation
of IL-6-inducible hepcidin (HAMP), an iron regulatory
hormone known to block iron export and uptake [35].
Down-regulation of hemoglobin mRNA may also be
related to a block in erythropoiesis caused by interferon
[36]; since interferon levels are higher in virulent than in
benign infection of primates [3]. The down-regulation of
hemoglobin genes has been validated by quantitative PCR
(Table 2).
As mentioned earlier, LCMV infection is predicted to pro-
mote significant amino acid breakdown by gluconeogen-
esis. Three amino acid catabolic enzymes, arginase
(ARG2), serine dehydratase (SDS), and glutamic-
oxaloacetic transaminase (GOT1), were not altered in
Table 7: Expression of genes involved with complement and coagulation cascades in LCMV-WE-infected macaque liver
Pre-viremic Viremic
GenBank Accession no. Symbol Gene description Fold changea pb Fold changea pb
NM_000014 A2M Alpha-2-macroglobulin 3.31 0.0219 2.71 0.0417
NM_000491 C1QB Complement component 1, q subcomponent, B 
chain
3.65 0.1140 12.2 0.0029
AI184968 C1QC Complement component 1, q subcomponent, C 
chain
1.47 0.5402 3.27 0.0140
AL573058 C1R Complement component 1, r subcomponent 2.20 0.0287 2.73 0.0054
BC007010 C1S Complement component 1, s subcomponent 53.44 0.0006 50.21 0.0004
NM_000592 C4A/C4B Complement component 4A (Rodgers blood 
group)///complement component 4B 
(Childo blood group)
5.20 0.0002 6.32 0.0001
NM_000716 C4BPB Complement component 4 binding protein, beta 3.22 0.0401 5.65 0.0032
NM_001735 C5 Complement component 5 8.75 0.0015 7.83 0.0013
J05064 C6 Complement component 6 3.24 0.0332 2.63 0.0624
NM_000587 C7 Complement component 7 2.34 0.1850 4.28 0.0152
M17263 C8G Complement component 8, gamma polypeptide 4.72 0.0051 4.56 0.0038
AL570661 CD46 CD46 molecule, complement regulatory protein 4.72 0.0015 3.24 0.0060
X04697 CFH Complement factor H 2.90 0.0124 2.86 0.0091
NM_000506 F2 Coagulation factor II (thrombin) 2.11 0.0329 1.65 0.1360
AA910306 F5 Coagulation factor V (proaccelerin, labile factor) 3.16 0.0218 2.47 0.0071
NM_000504 F10 Coagulation factor X 2.42 0.0070 1.85 0.0513
NM_000128 F11 Coagulation factor XI 
(plasma thromboplastin antecedent)
-2.28 0.0150 -2.75 0.0029
NM_021871 FGA Fibrinogen alpha chain 3.86 0.0035 3.48 0.0039
BG545288 FGB Fibrinogen beta chain 49.86 0.0001 45.56 0.0001
NM_000509 FGG Fibrinogen gamma chain 2.67 0.0355 2.56 0.0325
M74220 LPA/PLG Lipoprotein, Lp(a)///plasminogen 4.69 0.0256 3.81 0.0396
NM_000892 KLKB1 Kallikrein B, plasma (Fletcher factor) 1 -1.70 0.1730 -2.32 0.0207
AI274095 MASP1 Mannan-binding lectin serine peptidase 1 
(C4/C2 activating component of Ra-reactive 
factor)
3.07 0.0004 2.78 0.0005
AB008047 MASP2 Mannan-binding lectin serine peptidase 2 4.75 0.0144 3.16 0.0489
NM_000242 MBL2 Mannose-binding lectin (protein C) 2, soluble 
(opsonic defect)
3.18 0.0162 1.37 0.5910
BE880828 MCFD2 Multiple coagulation factor deficiency 2 11.71 0.0004 14.72 0.0001
M74220 PLG Plasminogen 3.86 0.0059 3.60 0.0054
NM_000295 SERPINA1 Serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), 1
8.20 0.0003 7.21 0.0004
BC022309 SERPINC1 Serpin peptidase inhibitor, clade C (antithrombin), 
member 1
30.65 0.0005 19.29 0.0009
NM_000062 SERPING1 Serpin peptidase inhibitor, clade G (C1 inhibitor), 
member 1
2.77 0.0336 3.07 0.0296
BF511231 TFPI Tissue factor pathway inhibitor 
(lipoprotein-associated coagulation inhibitor)
2.05 0.0312 1.45 0.2590
a Mean fold changes were calculated using a division of raw expression values between experimental sample and uninfected control.
b All samples were analyzed separately. Changes in gene expression with a cutoff of 2.0-fold increased or decreased expression was used and, the p-
value was calculated by Student's t-test. Data are displayed only where the, p ≤ 0.05. This p-value was used as a measure of the magnitude of the 
difference between groups and to determine significance of the modulation. The modulated genes in the pathway are listed in alphabetic order.Virology Journal 2009, 6:20 http://www.virologyj.com/content/6/1/20
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their expression when comparing infected versus unin-
fected samples, yet there was a significant down-regula-
tion of these genes when comparing LCMV-WE-infected
to LCMV-non-diseased samples (Figure 4). This means
that transcripts from mildly-infected samples are up-regu-
lated with respect to transcripts from uninfected liver. The
up-regulation of these samples in mild infections has
been validated by quantitative PCR (Table 2). A similar
pattern has been observed for peroxisome proliferators-
activated receptor gamma (PPARGC1A), hemoglobin α1/
α2 (HBA 1–2) and follistatin (FST) (Figure 4), and has
been validated by quantitative PCR (Table 2). It is likely
that increased expression of these genes protects animals
with mild infections from a more severe disease.
PPP1R3C is the most dramatically up-regulated transcript
in virulently-infected livers with respect to mildly-infected
liver samples (156-fold in the pre-viremic stage), and this
up-regulation has been validated by quantitative PCR
(Table 2). PPP1R3C encodes an inhibitory subunit of pro-
tein phosphatase and is known to bind liver glycogen in
response to high levels of insulin. It belonging to a family
of pro-inflammatory genes with short-lived-mRNA con-
trolled by AU-rich elements in their 3'UTR [37]. Expres-
Listing of the most differentially-modulated genes in liver with respect to infected-but not-diseased samples Figure 4
Listing of the most differentially-modulated genes in liver with respect to infected-but not-diseased samples. 
There are clear differences between infected and uninfected samples, but less frequently, there are also differences between 
virulently-infected and mildly-infected samples and the most prominent genes in this latter category are highlighted in this fig-
ure. WE1 vs uninf (or vs nodisease) refers to pre-viremic samples (day 1–3) and WE2 vs uninf (or vs nodisease) refers to 
viremic samples (day 4–7). N-fold refers to fold up- or down-regulation of each gene expressed in a virulently-infected liver in 
relation to expression in an uninfected or non-diseased liver. Gene accession number, gene symbol and description of each 
gene are shown. Red or green color corresponds to up- or down-regulation of gene expression, respectively. This figure is a 
subset of Additional File 8.
GenBank    Gene Description
Acc. # symbol
NM_001105 ACVR1 Activin A receptor, type I
AF202889 APOA5 Apolipoprotein A-V
U75667 ARG2 Arginase, type II
BG435404 ARL4 CADP-ribosylation factor-like 4C
NM_012118 CCRN4L CCR4 carbon catabolite repression 4-like
BE221212 COL1A1 Collagen, type I, alpha 1
AI246687 CTSC Cathepsin C
NM_000783 CYP26A1 Cytochrome P450, family 26, subfamily A, polypeptide 1
NM_001443 FABP1 Fatty acid binding protein 1, liver
AK001699 FBXO21 F-box protein 21
AW080845 FOXP1 Forkhead box P1
NM_013409 FST Follistatin
BC020700 G6PC Glucose-6-phosphatase, catalytic subunit
BC000498 GOT1 Glutamic-oxaloacetic transaminase 1, soluble 
NM_021175 HAMP Hepcidin antimicrobial peptide
NM_000558 HBA1 Hemoglobin, alpha 1
V00489 HBA1-2 Hemoglobin, alpha 1 /// hemoglobin, alpha 2
BC005931 HBA1-2 Hemoglobin, alpha 1 /// hemoglobin, alpha 2
M25079 HBB Hemoglobin, beta
AF059180 HBB Hemoglobin, beta
NM_017912 HERC6 Hect domain and RLD 6
NM_001540 HSPB1 Heat shock 27kDa protein 1 
NM_006417 IFI44 Interferon-induced protein 44
M13436 INHBA Inhibin, beta A (activin A)
NM_005538 INHBC Inhibin, beta C
AF073310 IRS2 Insulin receptor substrate 2
NM_005101 ISG15 ISG15 ubiquitin-like modifier
NM_006033 LIPG Lipase, endothelial
BE880828 MCFD2 Multiple coagulation factor deficiency 2
NM_005863 NET1 Neuroepithelial cell transforming gene 1
NM_002591 PCK1 Phosphoenolpyruvate carboxykinase 1
NM_013261 PPARGC1A Peroxisome proliferator-activated receptor gamma, coactivator 1 a
N26005 PPP1R3C Protein phosphatase 1, regulatory subunit 3C
NM_006843 SDS Serine dehydratase
BC002704 STAT1 Signal transducer and activator of transcription 1, 91kDa
BC004188 TUBB2C Tubulin, beta 2C
NM_004223 UBE2L6 Ubiquitin-conjugating enzyme E2L 6
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sion of PPP1R3C has been associated with
encephalopathy [38].
Additional notable differences between virulent and mild
infections are large increases in expression of genes for
activin receptor (ACVR1) and inhibin (INHBA, INHBC),
along with a decrease in expression of follistatin (FST); all
of which belong to the transforming growth factor beta
(TGF-β) gene family. Expression of these TGF-β family
genes was validated by real-time quantitative PCR (Table
2). Though the gene for TGF-β was not differentially
expressed during LCMV infection, the protein was detect-
able in plasma during the viremic stage [3]. Follistatin is
known to bind and inactivate inhibin, and the down-reg-
ulation of FST is related to the rise in INHB and ACVR1
expression [39]. The inhibins act as negative regulators of
B cell development [40], which may contribute to LCMV-
mediated suppression of anti-viral immune responses.
Discussion
The LCMV-infected monkey model for Lassa fever was
investigated with the goal of finding transcriptome
changes that could eventually be used as prognostic
biomarkers to discriminate virulent and mild infections.
Transcriptome analysis of rhesus macaque liver showed
that both mild and virulent LCMV infections had tremen-
dous effects on glucose, amino acid and fatty acid metab-
olism, and on the complement and coagulation cascades.
As with our previous transcriptome analysis using blood
[3], prominent expression of inflammatory-response
genes was also seen in liver.
A transcriptome study using the HuH-7 liver cell line [41]
showed that Lassa infection up-regulated only laminin-a
and ribosomal protein L28 with respect to gene expres-
sion in uninfected cells. It is frequently observed that stud-
ies of single cell types will show few differences in
comparison to studies of complex tissues. Although our
study did not see changes in expression of the laminin-a
gene, several ribosomal protein genes were up-regulated
in LCMV-infected liver: approximately 30 were moder-
ately up-regulated, and 20 were highly up-regulated, with
L28 being the most up-regulated of all (Additional File 8).
None of the ribosomal gene expression changes observed
in LCMV-infected liver differed significantly when com-
paring the virulent and mild infections. It is possible that
L28 is a co-factor of arenavirus replication, since replicat-
ing LCMV is associated with ribosomal protein complexes
[42-44].
Other liver transcriptome studies have identified major
molecular events associated with viral infection, with
higher levels of interferon-responsive genes being a com-
mon theme. We observed significant up-regulation of
ISG15, IFIT1, and STAT1 in LCMV-WE-infected (diseased)
monkey liver with respect to non-diseased liver, and sim-
ilar increased expression was seen in human liver infected
with hepatitis C virus [45]. As noted in a recent paper on
the Ebola virus transcriptome [46], the majority of cells
profiled are uninfected bystanders and are responding to
plasma interferon despite the interferon-antagonistic
activity of viral genes within infected cells [47]. In two
liver transcriptome studies of human beings infected with
hepatitis C virus, MHC class I and II genes were up-regu-
lated in infected versus uninfected liver [45,48]; in our
studies, several MHC genes are up-regulated in liver, with
concomitant down-regulation in PBMC [3], possibly due
to migration of activated monocytes from the circulation
to infected sites. A noteable difference between the hepa-
titis C liver transcriptome and the LCMV-liver transcrip-
tome is that Serpin D1 and C genes are down-regulated by
hepatitis C, whereas Serpin C is 30-fold up-regulated in
the LCMV liver (Figure 2) and would be expected to
inhibit the intrinsic coagulation pathway.
Two crucial liver functions are glycogen breakdown and
gluconeogenesis from non-sugars like fatty acids, pyru-
vate, lactate, and amino acids, with both functions begin-
ning a few hours after the onset of fasting. Elevated rates
of fat breakdown (lipolysis) increase the release of free
fatty acids that simultaneously stimulate gluconeogenesis
and inhibit glycogenolysis [49,50]. The oxidation of fatty
acids by liver mitochondria leads to the generation of
ketone bodies, which appear in the blood in inverse pro-
portion to glucose and provide an important alternative
fuel source [51,52]. In LCMV-infected monkey liver there
was a significant increase in transcripts promoting gluco-
neogenesis in both stages of infection and a decrease in
transcripts promoting glycogenolysis (e. g. G6PC and
FBP1) in the early stage of infection. It is likely that gluco-
neogenesis was driven by hydrolysis of triglycerides since
transcripts for β-oxidation enzymes and lipases were up-
regulated in LCMV-infected livers (Table 6). Glycolysis
and gluconeogenesis constituted a "futile cycle" that
would be predicted to waste energy during LCMV infec-
tion (Table 2). During the early stage of infection the
macaque liver increased the usage of fatty acids and
ketone bodies, and later in the infection, the liver func-
tioned in a glucose-producing role, using amino acids and
fatty acids as an energy source.
Other viral infections are also inter-twined with glucose,
amino acid and fatty-acid metabolism. The transcription
of hepatitis B virus, a DNA virus, requires a key regulatory
enzyme of gluconeogenesis, peroxisome proliferator-acti-
vated receptor γ C1 (PPARGC1[53]. This enzyme acts
through nuclear receptors (the glucocorticoid receptor,
the forkhead transcription factor, and the nuclear receptor
4a) to stimulate transcription of hepatitis B. PPARGC1 is
known to be up-regulated by fasting, cold temperature orVirology Journal 2009, 6:20 http://www.virologyj.com/content/6/1/20
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stress [53], and, remarkably, it is significantly up-regu-
lated in the mild LCMV infection but not in the virulent
infection; this has been validated by quantitative PCR
(Table 2). Another glycolytic enzyme, phosphoglycerate
kinase (PGK), stimulates Sendai virus transcription
through its interaction with tubulin in the initiation com-
plex [54]. Vero cells infected with the alphavirus, Mayaro,
have altered glucose metabolism and increased glucose
consumption [55], but it is unclear whether this is directly
related to virus replication. The key glycolytic enzyme,
glyceraldeyde 3-phosphate dehydrognase (GAPDH) is
involved in the life cycle of parainfluenza virus type 3
(HPIV3) [56]. Interestingly, the genes for both PGK and
GAPDH were strongly up-regulated in both mild and vir-
ulent LCMV infections. Hepatitis C virus (HCV) infection
also affects hepatic glucose metabolism. HCV down-regu-
lates insulin-receptor substrate genes (IRS1 and IRS2)
through up-regulation of suppressor of cytokine signaling
(SOCS) [57]. Similarly in the LCMV-infected primate,
IRS1 expression is decreased and expression of IRS2 is
moderate, but SOCS2 is up-regulated (7.2-fold) at the pre-
viremic stage of infection (Additional File 8).
The acute LCMV disease has characteristics of starvation
that resemble both cachexia (TNF-α or IL-6-mediated
wasting) and anorexia (appetite loss). High levels of IL-6
were detected in LCMV-WE-infected liver [6]. IL-6 is
known to stimulate protein catabolism in order to main-
tain glucose levels via gluconeogenesis [24], whereas ano-
rexia, is largely driven by IL-1β [58] and is known to
mobilize fat stores in lieu of protein stores [24]. Here,
though we failed to detect increases in IL-1β, we observed
increased expression of both lipid-oxidation and protein
catabolism genes. We also observed an early decrease in
blood triglycerides (Table 1) that corroborates our tran-
scriptome result of suppressed ACACB. The low triglycer-
ides we observe also contrast with the profile of bacterial
sepsis in which high liver IL-6 coincides with high triglyc-
erides [59]. Although high IL-6 is detected by day 7 [6]
high circulating triglycerides are not seen until day 11 or
12 in the LCMV-WE-infected macaques (Table 1).
It is difficult to relate changes in intermediary metabolism
of LCMV-infected liver to a lethal disease that resembles
Lassa fever. Although the liver transcriptome may resem-
ble that of a starving organism, and such a profile is sup-
ported by the dehydration and appetite-loss observed in
diseased monkeys, it is known that primates can survive
weeks of starvation [51]; so it is unlikely that starvation
alone explains such a rapid disease. Since most of the tran-
scriptome changes that affected intermediary metabolism
were seen in both the diseased and non-diseased animals
it is unlikely that those changes were the primary cause of
disease. Importantly, several genes involved in intermedi-
ary metabolism (ARG2, GOT1, G6PC, IRS2, LIPG, PCK1,
SDS, PPARGC1) were considerably more up-regulated in
the mild than in the fatal infections (Figure 4) leading to
the possibility that the altered energy metabolism is pri-
marily a self-preserving rather than a pathogenic activity.
Some of the differences between virulently – and mildly-
infected liver could be ascribed to the over-expression of
interferon-response genes (e.g. IFI44, Figure 4). A large
drop in hemoglobin gene expression in virulent infections
was likely due to interferon inhibition of erythropoiesis
[36]. Paradoxically, circulating levels of red blood cells
and hemoglobin were unaffected by LCMV-WE infection
(Table 1), but events in the liver may precede what is
detectable in the circulation. A recent paper describes
lethal hemorrhagic anemia in LCMV-infected mice that
did not occur in IFN-α/β knockout mice [60]. In the
murine model, both LCMV-WE and LCMV-ARM caused
platelet dysfunction and life-threatening anemia. The
murine studies used much higher doses of virus than we
used for our primate pathogenesis studies, i. e. mice were
given 106 pfu virus, whereas the monkeys were given 103
pfu. Also, the disease in mice is generally considered
immunopathological, i.e. alleviated by immunosuppres-
sion, unlike the disease in guinea pigs and primates [61].
In the monkey model, only LCMV-WE replicates well in
monkey liver whereas LCMV-ARM replicates poorly [4],
and only LCMV-WE elicits detectable levels of interferon
in plasma [8]. Nevertheless, it is quite reasonable that in
the primate, IFN-α/β initiates platelet dysfunction, and it
might be reasonable to treat the primate disease with
platelet transfusions, as was done in the murine model.
Conclusion
Microarray analysis identified several potential gene
markers of LCMV-WE-associated liver disease. By investi-
gating changes in gene expression during the early stages
of disease we identified pathways most likely to be insti-
gating the disease signs observed during viral hemorrhagic
fever. Alterations in intermediary metabolism are more
likely a sign of active resistance than of pathogenesis.
Virus-mediated cytokine production could be responsible
for curtailed erythropoiesis and platelet dysfunction.
Changes in expression of genes in the coagulation cascade
could be directly responsible for capillary leakage and
thrombocytopenia in virulent LCMV infection.
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